itacitinib + osimertinib

The combination of **itacitinib** and **osimertinib** is an investigational regimen being studied primarily for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations that have progressed following EGFR tyrosine kinase inhibitor therapy. Itacitinib is an oral selective Janus kinase 1 (JAK1) inhibitor that modulates immune signaling and may help overcome immune-related mechanisms of cancer resistance. Osimertinib is a third-generation, irreversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that selectively targets both EGFR-sensitizing and EGFR T790M resistance mutations. This combination is under evaluation for its safety, tolerability, and antitumor activity in multiple phase 1/2 clinical trials for NSCLC.

Other names

itacitinib and osimertinibitacitinib plus osimertinib